Ahmed I.
- Country
- France
- Department
- Neurology
Research Overview
- Evaluation of Safety and Efficacy of L19TNF and Lomustine in Patients with Glioblastoma at First Progression
- Evaluation of SonoCloud-9 with Carboplatin Versus Lomustine or Temozolomide in First Recurrence Glioblastoma Post-Resection: A Randomized, Open-Label Trial
- Phase 1/2a Study of A49, A52, and Litenimod Sodium in Patients with Glioblastoma
Data & Insights
Has run more than one trial at 12 of 55 partner sites.
Specializations
Neuro-Oncology
Specializes in treating glioblastoma, focusing on both newly diagnosed and recurrent cases. The investigator explores innovative therapeutic approaches including ultrasound-induced blood brain barrier opening in combination with standard treatments.
- Primary Glioblastoma Management
- Recurrent Glioblastoma Treatment
- Blood-Brain Barrier Modulation
Incorporates advanced treatment modalities including tumor treating fields and targeted chemotherapy protocols.
Immunotherapy Research
Conducts studies on novel immunotherapeutic approaches, including antibody-cytokine fusion proteins and vaccine-based treatments for brain tumors. Investigates immune response in neurological conditions.
- Cancer Vaccines
- Targeted Antibody Therapy
- T-Cell Response Analysis
Explores specific immune markers including PTPRZ1 and TERT in brain cancer treatment.
Neurological Infections
Investigates treatment approaches for progressive multifocal leukoencephalopathy (PML) in immunocompromised patients. Focuses on immune checkpoint inhibition therapy using pembrolizumab.
- PML Management
- JC Virus Treatment
- Immunocompromised Patient Care
Specializes in treating neurological complications in immunosuppressed patients without HIV infection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.